SeaStar posts early QUELIMMUNE sales but faces cash crunch, dilution and Nasdaq notice

Quick take - SeaStar Medical Holding Corporation (NASDAQ: LMAO)

SeaStar (LMAO) is transitioning from R&D to commercial stage after FDA HDE approval for its pediatric SCD (QUELIMMUNE). The company is showing early product revenue but remains loss-making, cash-constrained and faces shareholder/legal and Nasdaq listing risks.

Key facts & metrics (from 10‑Q, amounts shown as reported)

* Period covered: Quarterly period ended June 30, 2025 (condensed consolidated, unaudited).

* Cash: $6,302 (as reported; table in thousands - ≈ $6.3M) at June 30, 2025 vs $1,819 at Dec 31, 2024.

* Total assets: $8,383 (in thousands) vs $4,658 at Dec 31, 2024.

* Total liabilities: $5,042 (in thousands) at June 30, 2025 vs $6,841 at Dec 31, 2024.

* Stockholders' equity/(deficit): $3,341 (in thousands) at June 30, 2025 vs (2,183) at Dec 31, 2024.

* Shares outstanding: 17,343,269 at June 30, 2025 (vs 5,977,246 at Dec 31, 2024).

* Net revenue: Three months ended June 30, 2025 - $338; Six months ended June 30, 2025 - $631 (in thousands).

* Gross profit: Q2 2025 - $311; Six months - $604 (in thousands).

* Operating expenses (Q2 2025): R&D $1,037; G&A $1,030; total operating expenses $2,067 (in thousands).

* Net loss: Q2 2025 - $(2,002); Six months 2025 - $(5,774) (in thousands).

* Net loss per share, basic and diluted: Q2 2025 - $(0.18); Six months 2025 - $(0.58).

* Weighted‑average shares outstanding (basic & diluted): Q2 2025 - 11,329,517; Six months - 9,981,215.

* Warrants outstanding (total): 18,874,301 as of June 30, 2025 (equity‑classified warrants 18,624,781; liability‑classified 249,520).

What's happening inside the company - operations & corporate actions

* Commercial rollout: QUELIMMUNE (pediatric SCD) was FDA‑approved under an HDE on Feb 21, 2024; first commercial shipments began July 2024. As of June 30, 2025 the company reports six customer sites and recognized $631 (thousands) revenue in the first half of 2025.

* Clinical program: Pivotal adult SCD trial (Neutralize‑AKI) ongoing - critical to any meaningful revenue expansion beyond pediatric sales.

* Headcount and operations: 18 employees as of June 30, 2025; inventory recognized for the first time (Inventory $77 at June 30, 2025).

* Financing activity: Multiple capital raises in 2024-2025 - February 2025 Offering (~$6.0M gross), June 2025 Offering (~$4.0M gross), ATM program (~$6.8M raised through June 30, 2025). SEPA with Lincoln Park provides a capacity up to $15.0M (commitment fee of 236,406 shares issued).

* Subsequent events (post‑period): July 2025 and August 2025 registered/direct offerings announced/closed (additional shares and warrants issued) - management is actively raising equity after quarter end.

Income statement - positives

* First commercial revenue recognized: Revenue of $338 (Q2) and $631 (six months) - proof of commercialization beginning after HDE approval and first shipments.

* Gross profit positive: Gross profit of $311 (Q2) and $604 (six months) - product economics on earliest sales show positive gross margin (cost of goods sold modest: $27 for the quarter).

* Operating expense discipline: Meaningful reduction vs prior year - R&D down 56% Q2 (from $2,334 to $1,037) and G&A down 56% Q2 (from $2,335 to $1,030). Total operating expenses fell materially vs 2024.

* Improved loss profile: Net loss reduced vs prior year periods ($5,774 six months 2025 vs $15,933 six months 2024) - driven largely by lower non‑operating fair‑value losses and reduced operating spend.

Income statement & financial position - negatives / risks

* Still loss‑making: Net loss of $(2,002) (Q2) and $(5,774) (six months) - recurring operating losses remain.

* Cash runway uncertainty / going concern: Company states cash on hand is not sufficient to fund operations for 12 months from issuance of the financials and "substantial doubt" exists about ability to continue as a going concern.

* Heavy dilution & overhang: Shares outstanding jumped to 17,343,269 (June 30, 2025) from 5,977,246 (Dec 31, 2024); nearly 19.2M potential dilutive securities excluded from EPS (warrants, options, RSUs). Large warrant pools (18.6M equity warrants) create dilution risk and overhang.

* Non‑operating volatility: Prior‑period fair‑value swings (convertible notes and warrant re‑measurements) materially affected 2024 results; while reduced in 2025, contingent instruments remain a reporting complexity.

* Nasdaq and legal risk: Received Nasdaq minimum‑bid notice (July 31, 2025) - 180 days to cure. Ongoing securities class action and derivative litigation (filed July-Dec 2024) - litigation exposure and distraction.

Near‑term catalysts and what to watch

* Adult pivotal trial data and regulatory pathway clarity - success would materially change revenue prospects.

* Cash and financing outcomes - draw on SEPA/ATM or completed August 2025 offering and July 2025 offering impact runway and Nasdaq compliance.

* Quarterly commercial traction - expansion beyond six pediatric sites and sustained order cadence for QUELIMMUNE.

* Warrant exercise dynamics and share count stabilization - monitor dilution from exercised pre‑funded warrants and future placements.

Bottom line

SeaStar (NASDAQ: LMAO) has moved from R&D to the early commercial phase with validated product sales and positive gross margins, and it has materially cut operating spend versus 2024. Those are positives. But the business remains loss‑making, dependent on scarce cash, faces substantial doubt about its ability to continue without further financing, carries large warrant/share overhang, and must cure Nasdaq bid‑price and broader liquidity risks. Investors should weigh early revenue and regulatory wins against persistent capital and execution risks.

Sources: SeaStar Medical Holding Corporation Form 10‑Q for the quarter ended June 30, 2025 (as filed with the SEC).